Nrx Pharmaceuticals, Inc. · NASDAQ:NRXP
Nrx Pharmaceuticals — Investor Presentation (June 2026)
21 slides from Nrx Pharmaceuticals's investor presentation, June 2026
Slide 1: Corporate Presentation – Hope.Science.Life
Hope.Science.Life Corporate Presentation June 2026
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER Certain statements contained in this presentation or in other documents of NRx Pharmaceuticals, Inc. (the “Company” or “NRXP”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material,
Slide 3: Corporate Highlights
CORPORATE HIGHLIGHTS Scalable Commercial Platform Major Sentiment Shift in Near-Term FDA Catalysts Scientific Leadership and via HOPE Therapeutics and Psychedelics Across Multiple Drug Programs Differentiated Pipeline Nationwide Partnerships Federal Policy Tailwinds: Trump Executive Recently complet
Slide 4: Federal Support Signals a Breakthrough Moment for the Psychedelic Drug Market
FEDERAL SUPPORT SIGNALS A BREAKTHROUGH MOMENT FOR THE PSYCHEDELIC DRUG MARKET “President Trump signed an executive order Saturday that seeks to fast-track research into certain psychedelic drugs, including LSD and ibogaine, which some veterans have used to treat their post-traumatic stress disorder.
Slide 5: Experienced Leadership with Proven Clinical, Regulatory and Commercialization Execution
EXPERIENCED LEADERSHIP WITH PROVEN CLINICAL, REGULATORY AND COMMERCIALIZATION EXECUTION Jonthan C. Javitt, MD, MPH Michael Abrams, MBA Glenn D. Tyson Riccardo Panicucci, PhD Founder, Chairman and CEO Chief Financial Officer Chief Commercial Officer Chief Manufacturing Officer Drug development at Mer
Slide 6: Suicide Is a National Crisis That Kills >49,000 Americans Every Year
SUICIDE IS A NATIONAL CRISIS THAT KILLS >49,000 AMERICANS EVERY YEAR Suicide takes our best and brightest Suicide can affect anyone – regardless of success, talent, or status Suicide is preventable. Together, we can save lives and bring hope to those who need it the most. Source: Centers for Disease
Slide 7: Depression Care Shows Significant Growth Opportunities
DEPRESSION CARE SHOWS SIGNIFICANT GROWTH OPPORTUNITIES Significant US and EU Market Opportunity ~45M+ TAM of 45M+ patients in 2024 for major depressive disorder (MDD) and PTSD 3 ~4M+ Market penetration for TMS has grown to ~8% of eligible patients Growth Potential: TMS is still only performed for ~8
Slide 8: Neuroplasticity: A New Era in Mental Health Treatment
“ NEUROPLASTICITY: A NEW ERA IN MENTAL HEALTH TREATMENT After 50 years of limited progress… “My hope is that we are able to Fifty years of miracles in treating infectious disease, heart disease, cancer, and other major causes of death transform the mental health therapeutic landscape in my lifetim
Slide 9: NRx Highly Strategic, Diversified Business Model
NRX PHARMACEUTICALS’ HIGHLY STRATEGIC, DIVERSIFIED BUSINESS MODEL COMBINES DEVELOPMENT OF KETAFREE, NRX-100, AND NRX-101 WITH A 20- CLINIC PLATFORM AND 400 APOLLO TMS INSTALLATIONS KetaFree (IV Ketamine Stabilization Therapy) HOPE Therapeutics (Clinics) ▪ Composition: Preservative-free IV ketamine ▪
Slide 10: Clinical Pipeline
NRx Pharmaceuticals Clinical Pipeline
Slide 11: Two Near-Term Drug Regulatory Milestones; Multi-Billion Dollar Opportunity in Psychiatry
TWO NEAR-TERM DRUG REGULATORY MILESTONES; MULTI-BILLION DOLLAR OPPORTUNITY IN PSYCHIATRY Depression with Suicidal Ideation Compound Indication Phase 1 Phase 2 Phase 3 Filed with FDA Market Potential (3) Generic, GDUFA date in Summer KETAFREE preservative- ANDA Filed and Received by FDA $750 million
Slide 12: Biologic Proof That Ketamine Rewires the Brain
BIOLOGIC PROOF THAT KETAMINE “REWIRES” THE BRAIN Chronic Stress Ketamine’s effect on neuronal dendritic spines High levels of NMDA activity are shown to cause atrophy of the "dendritic spines" that connect brain cells Dendrite Ketamine Infusion Baseline 2 Photons Imaging Loss of dendritic spines is
Slide 13: Multiple Clinical and Commercial Catalysts with Meaningful Value Inflection Potential
MULTIPLE CLINICAL AND COMMERCIAL CATALYSTS WITH MEANINGFUL VALUE INFLECTION POTENTIAL Clinical Execution Initiation of KetaFree Commercial Scale KETAFREE NDA FILING Manufacture FDA waived the $4.3 million Rolling submission of clinical Initiated NDA for NRX-100, Summer 2026: GDUFA goal NDA submissio
Slide 14: Clinical Results
NRx Pharmaceuticals Clinical Results
Slide 15: Established Ketamine Efficacy Data
ESTABLISHED KETAMINE EFFICACY DATA French Gov’t Funded: Ketamine NIH Funded: PCORI Funded: vs. Placebo(1) Ketamine vs. Midazolam(2) Ketamine vs. ECT(3) ▪ 156 Patients, 7 Hospitals ▪ 96 pt. Randomization to Ketamine vs. ▪ 400 pts. superiority favoring Ketamine ▪ Admitted with acute suicidality midazo
Slide 16: >65,000 Patients of Confirmatory Real-World Data
>65,000 PATIENTS OF CONFIRMATORY REAL-WORLD DATA IV Racemic Ketamine Has Demonstrated Greater Reduction in Depression Severity (PHQ-9) with Fewer Treatments IV Racemic Ketamine(1) Nasal S-Ketamine (Esketamine) (1) ✓ Doses: ~7 Doses: ~15 ✓ PHQ-9 Score: ~8.5 PHQ-9 Score: ~11.0 Source: Osmind. “Esk
Slide 17: Outcomes of TMS + Cycloserine (NRX-101)
OUTCOMES OF TMS + CYCLOSERINE (NRX-101) 100% Response Rate Remission Rate 90% 87% 80% 70% ▪ Results in two peer- 72% STAR*D Trial on Antidepressants Treatments reviewed studies when 66% 60% TMS is combined with D- 57% 56% cycloserine (NRX-101), a 50% known neuroplastic 48% 40% medication(1) 37% 37%
Slide 18: Case Studies – NRXP Is Committed to Supporting Military Personnel
CASE STUDIES – NRXP IS COMMITTED TO SUPPORTING MILITARY PERSONNEL 1. Impacts of Ongoing War PTSD and Acute Suicidal Ideation Partnering for the Future of Depression & Combat Stress Force Preparedness Demand for Rapid Intervention 2. Impact on War’s End DARPA – Improving Warfighter Post-War P
Slide 19: HOPE Therapeutics: Building a Scalable, Vertically Integrated Psychiatry Platform
HOPE THERAPEUTICS: BUILDING A SCALABLE, VERTICALLY INTEGRATED PSYCHIATRY PLATFORM Pharma Launch in 2026 with Clinical Amplification from HOPE Therapeutics Full Patient Journey Dual Engine Model Scale Why This Works Now ▪ Patients: Treatment-resistant ▪ Roll-Up Fragmented ▪ 2025: Launched and ramped
Slide 20: Partnering for a National Footprint
PARTNERING FOR A NATIONAL FOOTPRINT ▪ A Broad National Footprint: HOPE and neurocare have a combined base of 20 clinics together with 400 Apollo TMS installations in the US. ▪ Combination of owned and MSO clinics limits capital need and drives rapid growth ▪ Results that matter to Payers: Return to
Slide 21: Corporate Highlights
CORPORATE HIGHLIGHTS Scalable Commercial Platform Major Sentiment Shift in Near-Term FDA Catalysts Scientific Leadership and via HOPE Therapeutics and Psychedelics Across Multiple Drug Programs Differentiated Pipeline Nationwide Partnerships Federal Policy Tailwinds: Trump Executive Recently complet
NRx Pharmaceuticals — Investor Presentation (June 2026) on 6ix